After a long, cash-strapped journey, French biotech Abivax has presented top-line data from the twin phase 3 trials of its lead ulcerative colitis candidate.  | After a long, cash-strapped journey, ...

Investing.com -- Abivax shares rose over 400% in Paris on Wednesday after the French biotech company announced that its lead drug candidate obefazimod achieved primary endpoints in two Phase 3 ...

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis ...

Investing.com -- Abivax shares rose over 400% in Paris on Wednesday after the French biotech company announced that its lead drug candidate obefazimod achieved primary endpoints in two Phase 3 ...

Abivax reports positive phase 3 results from both ABTECT 8-week induction trials of obefazimod to treat moderate to severely active ulcerative colitis: Paris, France Thursday, Jul ...

Abivax SA (NASDAQ:ABVX) shares surged in post-market trading Tuesday after the French biotech firm announced successful Phase 3 trial results for its ulcerative colitis treatment, obefazimod. The oral ...

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis ...

The ABTECT program is one of the largest Phase 3 ulcerative colitis trials ever conducted. Abivax to host a conference call and webcast today at 4:30 p.m. EDT ( 10:30 p.m. CEST) to discuss the ...

Results from the Phase III ABTECT-1 (NCT05507203) and ABTECT-2 (NCT05507216) trials showed that Abivax’s obefazimod demonstrated significant clinical remission in patients with ulcerative colitis.

Abivax dazzled investors and analysts with positive data from a pair of Phase III induction trials assessing obefazimod in adults with moderately to severely active ulcerative colitis. The results ...